Holen Sie sich die Stockscreener-App
29.38
1.83%
-0.5688
Schlusskurs vom Vortag:
$29.95
Offen:
$29.9
24-Stunden-Volumen:
31,104
Relative Volume:
0.10
Marktkapitalisierung:
$2.04B
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-3.57%
1M Leistung:
+3.31%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$29.21
$30.59
1-Wochen-Bereich:
$29.27
$31.06
52-Wochen-Spanne:
$18.84
$38.54
Alamar Biosciences Inc Stock (ALMR) Company Profile
Firmenname
Alamar Biosciences Inc
Sektor
Branche
Telefon
510-626-9888
Adresse
47071 BAYSIDE PARKWAY, FREMONT
Compare ALMR vs ABT, MDT, SYK, BSX, EW
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
ALMR
Alamar Biosciences Inc
|
29.38 | 2.08B | 0 | 0 | 0 | 0.00 |
ABT
Abbott Laboratories
|
106.24 | 182.59B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
92.58 | 118.18B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
274.67 | 106.03B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
45.45 | 65.19B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
86.46 | 49.99B | 6.30B | 1.07B | 1.09B | 1.8406 |
Alamar Biosciences Inc Aktie (ALMR) Neueste Nachrichten
Alamar Biosciences, Inc. Common Stock (NASDAQ: ALMR) Stock Price, News & Analysis - Kalkine
Ragusa Robert P. Acquires 5,686 Shares and 25,599 Derivative Securities of Alamar Biosciences - Kalkine Media
Alamar Biosciences (ALMR) director has no reported share holdings - Stock Titan
Alamar Biosciences Slides After Conference Hype Fades - TipRanks
Alamar Biosciences to Participate in Morgan Stanley 24th Annual Global Healthcare Conference - The Manila Times
Alamar Biosciences, Inc. Announces Appointment of Robert Ragusa as Director and Member of Audit Committee, Compensation Committee, and Nominating and Corporate Governance Committee, Effective September 1, 2026 - marketscreener.com
Alamar Biosciences expands proteomics partnership by 86,000 samples - Investing.com Nigeria
Alamar Biosciences (ALMR) Q2 2026 Earnings Call Transcript - The Globe and Mail
Alamar Biosciences: Promising But Expensive Proteomics Growth - Seeking Alpha
Alamar Stock: The Content Flywheel Is More Valuable Than The Instrument (ALMR) - Seeking Alpha
Alamar Biosciences (ALMR) Stock Price Jumps As Margin Gains Meet Loss Pressure - Sahm
Alamar Biosciences (ALMR): Yuling Luo discloses 6.4% beneficial ownership stake - Stock Titan
Alamar Biosciences, Inc. (ALMR) Q2 2026 Earnings ReportResults, Call & Slides - TipRanks
Analysts Offer Insights on NA Companies: Alamar Biosciences, Inc. (ALMR), NIQ Global Intelligence PLC (NIQ) and Amentum Holdings, Inc. (AMTM) - The Globe and Mail
Alamar Biosciences Shares (ALMR) Surge 31% as Consumables Drive Gross Margin Up - TechStock²
Alamar Biosciences (ALMR): Qiming funds report over 10% ownership stake - Stock Titan
Alamar Biosciences launches NULISAseq Immune 340 Panel for profiling - scanx.trade
Alamar Biosciences Q2 Results: Revenue Rises 82% To $29.4 Million - scanx.trade
Stifel raises Alamar Biosciences stock price target on earnings beat By Investing.com - Investing.com Canada
Alamar Biosciences Reports Q2 2026 Financial Results in Form 10-Q Filing - Kalkine Media
ALAMAR BIOSCIENCES INC : STIFEL RAISES TARGET PRICE TO $32 FROM $28 - Bitget
Alamar Biosciences Q2 2026 Earnings Call Transcript - MarketBeat
Alamar Biosciences, Inc. Stock 12‑Month Price Target Raised to $33.4, Implies 19% Upside - TradingView
Alamar Biosciences, Inc. 2Q 2026: Revenue $29.4M, EPS $(0.22) — 10-Q Summary - TradingView
Alamar Biosciences Inc (ALMR) (Q2 2026) Earnings Call Highlights: Revenue Surges 82% on 147% ... - Yahoo Finance Singapore
Alamar Biosciences (ALMR) Stock Trades At A Premium To Its Sales - Yahoo Finance
Alamar Biosciences to report Q2 2026 results on August 10, 2026 - scanx.trade
Form 8K Alamar Biosciences For: 10 August By Investing.com - Investing.com Nigeria
Alamar Biosciences Q2 Earnings Call Highlights - MarketBeat
Alamar Biosciences Q2 revenue surges 82%, led by consumable demand - scanx.trade
Alamar Biosciences Inc reports results for the quarter ended June 30Earnings Summary - TradingView
Earnings call transcript: Alamar Biosciences posts strong Q2 2026 revenue growth - Investing.com
Alamar Biosciences, Inc. 2026 Q2ResultsEarnings Call Presentation (NASDAQ:ALMR) 2026-08-10 - Seeking Alpha
ALAMAR BIOSCIENCES ($ALMR) Releases Q2 2026 Earnings - quiverquant.com
Alamar: Q2 Earnings Snapshot - Yahoo Finance
Earnings Flash (ALMR) Alamar Biosciences Posts Q2 Loss Per Share $0.22, Vs. FactSet Est of $0.31 Loss - Moomoo
Alamar Biosciences Reports Second Quarter 2026 Financial Results and Provides 2026 Revenue Guidance - The Manila Times
Earnings Flash (ALMR) Alamar Biosciences, Inc. Reports Q2 Revenue $29.4M, Vs. FactSet Est of $25.9M - Moomoo
Alamar Biosciences Expands Global Partnership with Alzheimer’s Disease Data Initiative and Gates Ventures - GlobeNewswire
Alamar Biosciences (ALMR) Introduced Its NULISAseq Immune 340 Panel - Sahm
Alamar Biosciences Inc expected to post a loss of 33 cents a shareEarnings Preview - TradingView
Alamar Biosciences, Inc. (ALMR) stock price, news, quote and history - Yahoo Finance Australia
Alamar Biosciences Launches NULISAseq™ Immune 340 Panel for Comprehensive Profiling of the Immune Proteome - The Manila Times
Alamar Biosciences launches immune profiling panel for research By Investing.com - Investing.com Nigeria
Alamar Biosciences Inc. (ALMR) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Alamar Biosciences, Inc. Revenue Breakdown – NASDAQ:ALMR - TradingView
Alamar Biosciences, Inc. (ALMR) Stock Price, News, Quote & History - Yahoo! Finance Canada
Finanzdaten der Alamar Biosciences Inc-Aktie (ALMR)
Es liegen keine Finanzdaten für Alamar Biosciences Inc (ALMR) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
Alamar Biosciences Inc-Aktie (ALMR) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| Naclerio Nicholas | Director |
Apr 20 '26 |
Buy |
17.00 |
235,294 |
3,999,998 |
507,076 |
0.72%
0.85%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):